Prothena Corporation News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

04.05.22	Ausblick: Prothena präsentiert Bilanzzahlen zum jüngsten Jahresviertel (finanzen.net)
28.04.22	Prothena to Report First Quarter 2022 Financial Results on May 5th (GlobeNewswire)
26.04.22	Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease (GlobeNewswire)
28.03.22	Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease (GlobeNewswire)
21.03.22	Prothena to Participate in Stifel 2022 Virtual CNS Days (GlobeNewswire)
16.03.22	Prothena Presents New Data for Alzheimer’s and Parkinson’s Disease Programs at AD/PD 2022 (GlobeNewswire)
17.02.22	Prothena Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Financial Guidance and Business Highlights (GlobeNewswire)
16.02.22	Ausblick: Prothena mit Zahlen zum abgelaufenen Quartal (finanzen.net)
10.02.22	Prothena to Report Fourth Quarter and Full Year 2021 Financial Results and Host Webcast Conference Call on February 17, 2022 (GlobeNewswire)
29.11.21	Prothena to Participate in JMP Securities Hematology and Oncology Summit (GlobeNewswire)
04.11.21	Prothena Reports Third Quarter 2021 Financial Results and Business Highlights (GlobeNewswire)
03.11.21	Ausblick: Prothena zieht Bilanz zum jüngsten Jahresviertel (finanzen.net)
28.10.21	Prothena to Report Third Quarter 2021 Financial Results on November 4th (GlobeNewswire)
01.10.21	Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
01.10.21	Prothena Announces Executive Appointments (GlobeNewswire)
28.09.21	Prothena Reclaims Lost Glory (RTTNews)
03.09.21	Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
01.09.21	Prothena to Participate in Upcoming September Healthcare Conferences (GlobeNewswire)
05.08.21	Prothena Reports Second Quarter 2021 Financial Results and Business Highlights (GlobeNewswire)
03.08.21	Ausblick: Prothena stellt Zahlen zum jüngsten Quartal vor (finanzen.net)
29.07.21	Prothena to Report Second Quarter 2021 Financial Results on August 5th (GlobeNewswire)
26.07.21	Prothena Presents New Data from Robust Alzheimer’s Portfolio at the Alzheimer’s Association International Conference 2021 (GlobeNewswire)
20.07.21	Prothena to Present Data from Two of its Alzheimer’s Disease Programs at the Alzheimer’s Association International Conference 2021 (GlobeNewswire)
12.07.21	Prothena Sells ATTR Amyloidosis Programme To Novo Nordisk For Up To $1.2 Bln - Quick Facts (RTTNews)
12.07.21	Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena’s ATTR Amyloidosis Programme (GlobeNewswire)
24.06.21	Prothena To Receive $80 Mln From Bristol Myers For US License To PRX005 On Alzheimer's Disease (RTTNews)
24.06.21	Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration (GlobeNewswire)
10.06.21	Prothena to Participate in JMP Securities Life Sciences Conference on June 16 (GlobeNewswire)
20.05.21	Prothena Announces Appointment of Sanjiv Patel, MBBS, to its Board of Directors (GlobeNewswire)
11.05.21	Prothena Reports First Quarter 2021 Financial Results and Provides Updated Financial Guidance and R&D Update (GlobeNewswire)
10.05.21	Prothena Announces Achievement of $60 Million Milestone From Roche for First Patient Dosed in Phase 2b Study of Prasinezumab in Early Parkinson’s Disease (GlobeNewswire)
09.05.21	Ausblick: Prothena präsentiert Quartalsergebnisse (finanzen.net)
07.05.21	Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04.05.21	Prothena to Report First Quarter 2021 Financial Results on May 11th (GlobeNewswire)
18.04.21	Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021 (GlobeNewswire)
15.04.21	Prothena Announces PRX004 Phase 1 Study Results Selected for Emerging Science Oral Presentation at AAN 2021 (GlobeNewswire)
07.04.21	Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
05.04.21	Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer (GlobeNewswire)
24.03.21	Prothena Announces Pricing of Public Offering of 3,500,000 Ordinary Shares (GlobeNewswire)
23.03.21	Prothena Announces Proposed Offering of Ordinary Shares (GlobeNewswire)
08.03.21	Prothena to Hold Investor Webcast to Review Three Oral Presentations from AD/PD 2021 (GlobeNewswire)
28.02.21	Analysten sehen für Prothena-Aktie Luft nach oben (finanzen.net)
24.02.21	Prothena Announces Promising New Preclinical and Clinical Data from its Neurodegenerative Programs Selected for Oral Presentations at AD/PD 2021 (GlobeNewswire)
11.02.21	Prothena Reports Fourth Quarter and Full Year 2020 Financial Results, and Provides Financial Guidance and R&D Update (GlobeNewswire)
09.02.21	Ausblick: Prothena stellt das Zahlenwerk zum vergangenen Quartal vor (finanzen.net)
05.02.21	Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04.02.21	Prothena to Report Fourth Quarter and Full Year 2020 Financial Results and Host Webcast Conference Call on February 11th (GlobeNewswire)
02.02.21	ADMS Gets FDA Nod, ARQT Soars On Psoriasis Trial Data, DVAX Catches Eye, PRTA On Watch (RTTNews)
01.02.21	Prothena Announces Confirmatory Phase 3 AFFIRM-AL Study of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis under SPA Agreement with FDA (GlobeNewswire)
09.12.20	Prothena Reports Positive 9 Month Results from Phase 1 Long-term Extension Study of PRX004, the First Investigational Anti-Amyloid Immunotherapy for the Treatment of ATTR Amyloidosis (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	302.80	1.30 %	K V
Alcon	76.88	0.65 %	K V
Sika	218.00	0.37 %	K V
Kuehne+Nagel Int	202.60	-0.20 %	K V
Logitech Intl	78.28	-0.33 %	K V
ABB	49.25	-1.44 %	K V
Holcim	87.68	-1.55 %	K V
Zurich Insur Gr	531.20	-1.63 %	K V
Roche Hldg G	267.20	-1.69 %	K V
UBS Group	29.78	-1.94 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Prothena Corporation PLC

Aktien Top/Flop

Meistgelesene Nachrichten